MCID: ESP025
MIFTS: 46

Esophagus Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Esophagus Adenocarcinoma

MalaCards integrated aliases for Esophagus Adenocarcinoma:

Name: Esophagus Adenocarcinoma 12 14
Adenocarcinoma of Esophagus 12 42 69
Oesophageal Adenocarcinoma Nos 12

Classifications:



Summaries for Esophagus Adenocarcinoma

Disease Ontology : 12 An esophageal carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Esophagus Adenocarcinoma, also known as adenocarcinoma of esophagus, is related to barrett esophagus/esophageal adenocarcinoma and tendon sheath lipoma, and has symptoms including obesity, clinodactyly of the 5th toe and nausea and vomiting. An important gene associated with Esophagus Adenocarcinoma is CDO1 (Cysteine Dioxygenase Type 1), and among its related pathways/superpathways are Pathways in cancer and MicroRNAs in cancer. The drugs Menthol and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and colon, and related phenotypes are digestive/alimentary and endocrine/exocrine gland

Related Diseases for Esophagus Adenocarcinoma

Diseases related to Esophagus Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 151)
id Related Disease Score Top Affiliating Genes
1 barrett esophagus/esophageal adenocarcinoma 10.9
2 tendon sheath lipoma 10.8 PTGS2 TP53
3 brain ependymoma 10.7 ATP4A PTGS2
4 congenital disorder of glycosylation, type if 10.7 ERBB2 TP53
5 endocervicitis 10.7 ERBB2 TP53
6 cervical adenoid cystic carcinoma 10.7 CDKN2A TP53
7 animal phobia 10.7 ERBB2 TP53
8 split hand split foot nystagmus 10.6 CDKN2A TP53
9 extracranial neuroblastoma 10.6 ERBB2 TP53
10 leiomyoma cutis 10.6 CDKN2A TP53
11 deep angioma 10.6 TP53 WWOX
12 anal squamous cell carcinoma 10.6 CDKN2A TP53
13 colon neuroendocrine neoplasm 10.6 ERBB2 TP53
14 skeletal tuberculosis 10.6 CDKN2A ERBB2
15 brachial amelia, forebrain defects and facial clefts 10.6 CDKN2A PTGS2
16 rectum squamous cell carcinoma 10.6 CDKN2A TP53
17 neuroendocrine tumor 10.6 CDX2 PTGS2
18 breast myoepitheliosis 10.6 CDKN2A TP53
19 ritter's disease 10.6 CDKN2A TP53
20 cystic kidney disease 10.6 ERBB2 TP53
21 testis seminoma 10.6 CDKN2A ERBB2
22 chronic neutrophilic leukemia 10.6 CDKN2A CDX2
23 coccidiosis 10.6 CDKN2A TP53
24 scrotum melanoma 10.6 ATP12A ATP4A
25 duodenum cancer 10.6 CDKN2A TP53
26 congenital aphakia 10.6 ATP12A ATP4A
27 primary syphilis 10.6 ATP12A ATP4A
28 bone giant cell sarcoma 10.6 ATP12A ATP4A
29 urethral calculus 10.6 ATP12A ATP4A
30 vulva squamous cell carcinoma 10.6 CDKN2A ERBB2
31 hypopituitarism 10.6 ATP12A ATP4A
32 brenner tumor of the vagina 10.6 ERBB2 TP53
33 penis paget's disease 10.6 CDKN2A TP53
34 amyotrophic lateral sclerosis type 5 10.6 ATP12A ATP4A
35 abnormal pupillary function 10.6 ATP12A ATP4A
36 atheroembolism of kidney 10.5 ATP12A ATP4A
37 microphthalmia, syndromic 12 10.5 ATP12A ATP4A
38 synostosis 10.5 ATP12A ATP4A
39 vaginal carcinosarcoma 10.5 PTGS2 WWOX
40 muscle cancer 10.5 ATP12A ATP4A
41 retinal detachment 10.5 CDKN2A TP53
42 active vestibular meniere's disease 10.5 CDKN2A PTGS2
43 adult xanthogranuloma 10.5 ATP12A ATP4A
44 polysyndactyly with cardiac malformation 10.5 ATP12A ATP4A
45 brenner tumor of ovary 10.5 ERBB2 TP53
46 larynx carcinoma in situ 10.5 CDKN2A TP53
47 focal hand dystonia 10.5 ATP12A ATP4A
48 primary optic atrophy 10.5 TP53 WWOX
49 ovarian melanoma 10.5 CDX2 WWOX
50 cloacal exstrophy 10.5 ATP12A ATP4A

Graphical network of the top 20 diseases related to Esophagus Adenocarcinoma:



Diseases related to Esophagus Adenocarcinoma

Symptoms & Phenotypes for Esophagus Adenocarcinoma

Human phenotypes related to Esophagus Adenocarcinoma:

32 (show all 10)
id Description HPO Frequency HPO Source Accession
1 obesity 32 hallmark (90%) HP:0001513
2 clinodactyly of the 5th toe 32 hallmark (90%) HP:0001864
3 nausea and vomiting 32 frequent (33%) HP:0002017
4 gastroesophageal reflux 32 hallmark (90%) HP:0002020
5 lymphadenopathy 32 occasional (7.5%) HP:0002716
6 feeding difficulties in infancy 32 hallmark (90%) HP:0008872
7 esophageal carcinoma 32 hallmark (90%) HP:0011459
8 cough 32 frequent (33%) HP:0012735
9 barrett esophagus 32 hallmark (90%) HP:0100580
10 chest pain 32 frequent (33%) HP:0100749

MGI Mouse Phenotypes related to Esophagus Adenocarcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.09 ATP12A ATP4A CDKN2A CDX1 CDX2 ERBB2
2 endocrine/exocrine gland MP:0005379 10.07 CDX2 ERBB2 MYC PTGS2 TP53 WWOX
3 growth/size/body region MP:0005378 9.97 ATP12A CDKN2A CDO1 CDX2 ERBB2 MYC
4 homeostasis/metabolism MP:0005376 9.96 ATP12A ATP4A CDKN2A CDO1 CDX2 ERBB2
5 embryo MP:0005380 9.95 CDKN2A CDX1 CDX2 ERBB2 MYC PTGS2
6 neoplasm MP:0002006 9.7 CDKN2A CDX2 ERBB2 MYC PTGS2 TP53
7 reproductive system MP:0005389 9.56 WWOX CDKN2A CDO1 CDX2 ERBB2 MYC
8 skeleton MP:0005390 9.28 CDKN2A CDO1 CDX1 CDX2 ERBB2 MYC

Drugs & Therapeutics for Esophagus Adenocarcinoma

Drugs for Esophagus Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 201)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Menthol Approved Phase 4 2216-51-5 16666
2
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1 51-21-8 3385
3
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
4
Levoleucovorin Approved Phase 4,Phase 2,Phase 3,Phase 1 68538-85-2
5
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 61825-94-3 5310940 9887054 43805 6857599
6
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
7
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
8
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 59-30-3 6037
9
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1 58-05-9 143 6006
10
Camptothecin Experimental Phase 4,Phase 2,Phase 1 7689-03-4
11 Liver Extracts Phase 4,Phase 2,Phase 1
12 Antidotes Phase 4,Phase 2,Phase 3,Phase 1
13 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
14 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
15 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
16 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1
17 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1
19 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1
20 topoisomerase I inhibitors Phase 4,Phase 3,Phase 2,Phase 1
21 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
22 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1
23 Vitamin B Complex Phase 4,Phase 2,Phase 3,Phase 1
24 Vitamins Phase 4,Phase 2,Phase 3,Phase 1
25 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
26 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Antiemetics Phase 4
28 Antineoplastic Agents, Hormonal Phase 4
29 Autonomic Agents Phase 4
30 Gastrointestinal Agents Phase 4,Phase 3
31 glucocorticoids Phase 4
32 Hormone Antagonists Phase 4,Phase 2
33 Hormones Phase 4,Phase 2
34 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2
35 Methylprednisolone acetate Phase 4
36 Methylprednisolone Hemisuccinate Phase 4
37 Neuroprotective Agents Phase 4
38 Prednisolone acetate Phase 4
39 Prednisolone hemisuccinate Phase 4
40 Prednisolone phosphate Phase 4
41 Folate Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1
42 Vitamin B9 Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1
43
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
44
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
45
Capecitabine Approved, Investigational Phase 2, Phase 3, Phase 1 154361-50-9 60953
46
Cetuximab Approved Phase 2, Phase 3, Phase 1 205923-56-4 56842117 2333
47
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
48
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
49
Gefitinib Approved, Investigational Phase 3,Phase 2,Phase 1 184475-35-2 123631
50
Trioxsalen Approved Phase 3,Phase 2 3902-71-4 5585

Interventional clinical trials:

(show top 50) (show all 295)

id Name Status NCT ID Phase Drugs
1 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
2 Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer Recruiting NCT02366819 Phase 4 Oxaliplatin;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
3 Barretts oEsophageal Resection With Steroid Therapy Trial Recruiting NCT02004782 Phase 4 Prednisolone
4 Combination Chemotherapy in Treating Patients With Esophageal Cancer Unknown status NCT00041262 Phase 3 cisplatin;epirubicin hydrochloride;fluorouracil
5 Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002883 Phase 3 cisplatin;fluorouracil
6 Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002884 Phase 3 chemotherapy;cisplatin;fluorouracil
7 Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer Unknown status NCT00509561 Phase 2, Phase 3 capecitabine;cisplatin
8 Confocal Endomicroscopy for Barrett's Esophagus Completed NCT00487695 Phase 3
9 Surgery With or Without Radiation Therapy and Chemotherapy in Treating Patients With Esophageal Cancer Completed NCT00047112 Phase 3 cisplatin;fluorouracil
10 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Cancer of the Esophagus Completed NCT00002631 Phase 3 chemotherapy;cisplatin;fluorouracil
11 Surgery With or Without Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus Completed NCT00003118 Phase 3 cisplatin;fluorouracil
12 Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer Completed NCT00020787 Phase 3 cisplatin;fluorouracil
13 Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy Completed NCT01243398 Phase 3
14 Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer Completed NCT00978549 Phase 3 docetaxel;steroid therapy
15 Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer Completed NCT00861094 Phase 2, Phase 3 cisplatin;5-FU;oxaliplatin;Folinic Acid
16 Impact of Roux-En-Y Pouch Reconstruction Compared With Conventional Roux-En-Y Reconstruction on Health-Related Quality of Life in Patients Undergoing Total Gastrectomy for Adenocarcinoma Completed NCT01491698 Phase 3
17 Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus Recruiting NCT02509286 Phase 3 5-Fluorouracil;Leucovorin;Oxaliplatin;Docetaxel;Carboplatin;Paclitaxel
18 NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS) Recruiting NCT01726452 Phase 3 Epirubicin;Cisplatin;5 Flourouracil/ Capecitabine;Paclitaxel;Carboplatin
19 Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction Recruiting NCT01523015 Phase 2, Phase 3
20 STRETTA ,Radio Frequency Ablation (RFA) v/s Sham Therapy for the Treatment of Refractory GERD Recruiting NCT02935881 Phase 3
21 A Randomized, Controlled, Multicenter Study to Compare Preoperative Radiochemotherapy With Preoperative Chemotherapy in Patients With Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma Recruiting NCT03013010 Phase 3 Tegafur-Gimeracil-Oteracil Potassium;Oxaliplatin
22 Clinical Study of Time Optimizing of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer Recruiting NCT02628665 Phase 3 photosensitizer(photofrin)
23 Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) Recruiting NCT02564263 Phase 3 paclitaxel;docetaxel;irinotecan
24 Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma Recruiting NCT01404156 Phase 2, Phase 3 Epirubicin cisplatin 5-Fluorouracil
25 Comparison of Systematic Surgery Versus Surveillance and Rescue Surgery in Operable Oesophageal Cancer With a Complete Clinical Response to Radiochemotherapy Recruiting NCT02551458 Phase 2, Phase 3
26 Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Active, not recruiting NCT01196390 Phase 3 Carboplatin;Paclitaxel
27 A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia Active, not recruiting NCT00357682 Phase 3 Esomeprazole;Esomeprazole;Aspirin
28 Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery Active, not recruiting NCT01107639 Phase 3 cisplatin;docetaxel
29 Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer Active, not recruiting NCT00052910 Phase 3 cisplatin;epirubicin hydrochloride;fluorouracil;leucovorin calcium
30 Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma Unknown status NCT00964080 Phase 1, Phase 2 MBP-426/Leucovorin/5-FU
31 Panitumumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Advanced Esophageal or Gastroesophageal Junction Cancer Unknown status NCT01307956 Phase 2 oxaliplatin;leucovorin calcium;fluorouracil
32 Tethered Capsule Endoscope in Screening Participants for Barrett Esophagus Unknown status NCT00903136 Phase 1, Phase 2
33 Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus Unknown status NCT00003326 Phase 2 paclitaxel
34 Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Cancer of the Stomach or Esophagus Unknown status NCT00005607 Phase 2 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
35 Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer Unknown status NCT00006472 Phase 2 carboplatin;fluorouracil;paclitaxel
36 Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery Unknown status NCT00005876 Phase 2 rubitecan
37 Liposomal Doxorubicin in Treating Patients With Advanced Stomach Cancer Unknown status NCT00004236 Phase 2 pegylated liposomal doxorubicin hydrochloride
38 Study to Evaluate Safety and Efficacy of Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine (DCX) in Patients With Gastro-esophageal Cancer Unknown status NCT00865982 Phase 2 Docetaxel, Cisplatin, Capecitabine
39 Phase II Study of Neoadjuvant Taxotere, Cisplatin, and 5-Fluorouracil in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma Unknown status NCT00763646 Phase 2 Taxotere, Cisplatin, and 5-FU
40 Pre-operative Epirubicin, Cisplatin, and Capecitabine in Patients With Newly Diagnosed Localised Oesophageal Adenocarcinoma Completed NCT00220103 Phase 2 epirubicin, capecitabine, cisplatin
41 Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus Completed NCT00259987 Phase 2 Lapatinib (GW572016) oral tablets
42 Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma Completed NCT00583674 Phase 2 AMG 386 placebo;AMG 386 10mg/kg;AMG 386 3mg/kg;Cisplatin;Capecitabine;Cisplatin;Capecitabine;Cisplatin;Capecitabine
43 3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction Completed NCT00077545 Phase 2 triapine;cisplatin
44 Irinotecan in Treating Patients With Esophageal or Stomach Cancer Completed NCT00003748 Phase 2 irinotecan hydrochloride
45 Phase II Study of Irinotecan and Panitumumab Completed NCT00836277 Phase 2 Panitumumab;Irinotecan
46 Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia Completed NCT00591123 Phase 2 FOLFOX and Erlotinib
47 Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer Completed NCT00354679 Phase 2 cisplatin;irinotecan hydrochloride
48 Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction Completed NCT00891878 Phase 2 capecitabine;sunitinib malate
49 Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach Completed NCT00020761 Phase 2 irinotecan hydrochloride;paclitaxel
50 Celecoxib, Paclitaxel, and Carboplatin in Treating Patients With Cancer of the Esophagus Completed NCT00066716 Phase 2 carboplatin;celecoxib;paclitaxel

Search NIH Clinical Center for Esophagus Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma of esophagus

Genetic Tests for Esophagus Adenocarcinoma

Anatomical Context for Esophagus Adenocarcinoma

MalaCards organs/tissues related to Esophagus Adenocarcinoma:

39
Liver, Testes, Colon, Bone

Publications for Esophagus Adenocarcinoma

Articles related to Esophagus Adenocarcinoma:

id Title Authors Year
1
The clinical significance of cysteine dioxygenase type 1 methylation in Barrett esophagus adenocarcinoma. ( 28184414 )
2017
2
Epigenetic regulation on the gene expression signature in esophagus adenocarcinoma. ( 28049580 )
2016
3
In vivo molecular imaging of HER2 expression in a rat model of Barrett's esophagus adenocarcinoma. ( 24708360 )
2014
4
Esophagus adenocarcinoma in a young patient with celiac disease; Is celiac disease a predisposing factor for esophagus adenocarcinoma as well as squamous cell carcinoma? ( 26185881 )
2014
5
Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis. ( 21166737 )
2010
6
Gene expression profiling of esophageal cancer: comparative analysis of Barrett's esophagus, adenocarcinoma, and squamous cell carcinoma. ( 17236199 )
2007
7
Familiality in Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction. ( 16985029 )
2006
8
Meningeal carcinomatosis in patient with esophagus adenocarcinoma. ( 9105327 )
1997

Variations for Esophagus Adenocarcinoma

Expression for Esophagus Adenocarcinoma

Search GEO for disease gene expression data for Esophagus Adenocarcinoma.

Pathways for Esophagus Adenocarcinoma

Pathways related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 16)
id Super pathways Score Top Affiliating Genes
1 12.36 CDKN2A ERBB2 MYC PTGS2 TP53
2 12.13 CDKN2A ERBB2 MYC PTGS2 TP53
3 11.86 CDX1 CDX2 MYC
4 11.8 MYC PTGS2 TP53
5 11.77 MYC PTGS2 TP53
6 11.75 CDKN2A MYC TP53
7 11.68 CDKN2A ERBB2 MYC TP53
8
Show member pathways
11.64 ERBB2 MYC WWOX
9 11.61 MYC PTGS2 TP53
10 11.52 CDKN2A ERBB2 TP53
11 11.45 ERBB2 MYC TP53
12 11.42 ERBB2 MYC TP53
13 11.29 MYC PTGS2 TP53
14 10.79 CDKN2A ERBB2 MYC TP53
15 10.67 CDKN2A MYC TP53
16
Show member pathways
10.47 CDKN2A MYC TP53

GO Terms for Esophagus Adenocarcinoma

Biological processes related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell cycle arrest GO:0007050 9.63 CDKN2A MYC TP53
2 positive regulation of gene expression GO:0010628 9.58 ERBB2 MYC TP53
3 cellular response to hypoxia GO:0071456 9.54 MYC PTGS2 TP53
4 anterior/posterior axis specification GO:0009948 9.43 CDX1 CDX2
5 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.32 ATP12A ATP4A
6 replicative senescence GO:0090399 9.26 CDKN2A TP53
7 regulation of somitogenesis GO:0014807 9.16 CDX1 CDX2
8 negative regulation of immature T cell proliferation in thymus GO:0033088 8.96 CDKN2A ERBB2
9 cellular response to UV GO:0034644 8.8 MYC PTGS2 TP53

Molecular functions related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen GO:0016702 9.16 CDO1 PTGS2
2 sodium:potassium-exchanging ATPase activity GO:0005391 8.96 ATP12A ATP4A
3 hydrogen:potassium-exchanging ATPase activity GO:0008900 8.62 ATP12A ATP4A

Sources for Esophagus Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....